Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

[1]  J. Le Pecq,et al.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.

[2]  J. Fay,et al.  Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells , 2004, The Journal of experimental medicine.

[3]  E. Wagner,et al.  IL-4 Confers NK Stimulatory Capacity to Murine Dendritic Cells: A Signaling Pathway Involving KARAP/DAP12-Triggering Receptor Expressed on Myeloid Cell 2 Molecules1 , 2004, The Journal of Immunology.

[4]  L. Zitvogel,et al.  Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection 1 , 2004, The Journal of Immunology.

[5]  L. Zitvogel,et al.  Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells 1 , 2004, The Journal of Immunology.

[6]  J. Davoust,et al.  ER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells , 2003, Nature.

[7]  P. Paz,et al.  Exosomes as a Tumor Vaccine: Enhancing Potency Through Direct Loading of Antigenic Peptides , 2003, Journal of immunotherapy.

[8]  R. Steinman,et al.  Single Injection of CD34+ Progenitor-Derived Dendritic Cell Vaccine Can Lead to Induction of T-Cell Immunity in Patients With Stage IV Melanoma , 2003, Journal of immunotherapy.

[9]  J. Le Pecq,et al.  Production and characterization of clinical grade exosomes derived from dendritic cells. , 2002, Journal of immunological methods.

[10]  C. Théry,et al.  Indirect activation of naïve CD4+ T cells by dendritic cell–derived exosomes , 2002, Nature Immunology.

[11]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[12]  G. Schuler,et al.  Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.

[13]  Drew M. Pardoll,et al.  Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.

[14]  R. Steinman,et al.  Active immunization against cancer with dendritic cells: The near future , 2001, International journal of cancer.

[15]  L. Zitvogel,et al.  Dendritic Cell Maturation Overrules H-2d–Mediated Natural Killer T (Nkt) Cell Inhibition , 2001, The Journal of experimental medicine.

[16]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[17]  P. Coulie,et al.  A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Gerold Schuler,et al.  Dendritic Cells as Vectors for Therapy , 2001, Cell.

[19]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[20]  P. Ricciardi-Castagnoli,et al.  Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles1 , 2001, The Journal of Immunology.

[21]  C. Melief,et al.  Antigen Loading of MHC Class I Molecules in the Endocytic Tract , 2001, Traffic.

[22]  M. Mason,et al.  Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. , 2001, Journal of immunological methods.

[23]  H. Geuze,et al.  Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. , 2000, Journal of cell science.

[24]  A. Enk,et al.  Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells1 , 2000, The Journal of Immunology.

[25]  R. Steinman,et al.  Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. , 1999, The Journal of clinical investigation.

[26]  C. Chow,et al.  Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[28]  H. Geuze,et al.  Selective Enrichment of Tetraspan Proteins on the Internal Vesicles of Multivesicular Endosomes and on Exosomes Secreted by Human B-lymphocytes* , 1998, The Journal of Biological Chemistry.

[29]  Laurence Zitvogel,et al.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes , 1998, Nature Medicine.

[30]  H. Rammensee,et al.  Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ‐ELISPOT assay , 1997 .

[31]  H. Rammensee,et al.  Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. , 1997, International journal of cancer.

[32]  C. Melief,et al.  B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.

[33]  F. Brasseur,et al.  Expression of mage genes by non‐small‐cell lung carcinomas , 1994, International journal of cancer.